)
)
Exelixis Investor Relations Material
Latest events
Q3 2024
Exelixis
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Exelixis Inc
Access all reports
Exelixis, Inc., is a US-based biotechnology company within oncology. The company focuses on the discovery, development, and commercialization of new medicines to treat cancers in the U.S. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its products also comprise MINNEBRO tablets for the treatment of genetic conditions.
Key slides for Exelixis Inc
Q1 2024
Exelixis Inc
Q2 2024
Exelixis Inc
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
EXEL
Country
🇺🇸 United States